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Abstract: Binary toxins are produced by several pathogenic bacteria. Examples are the C2 toxin from
Clostridium botulinum, the iota toxin from Clostridium perfringens, and the CDT from Clostridium difficile.
All these binary toxins have ADP-ribosyltransferases (ADPRT) as their enzymatically active
component that modify monomeric actin in their target cells. The binary C2 toxin was intensively
described as a tool for intracellular delivery of allogenic ADPRTs. Here, we firstly describe the binary
toxin CDT from C. difficile as an effective tool for heterologous intracellular delivery. Even 60 kDa
glucosyltransferase domains of large clostridial glucosyltransferases can be delivered into cells. The
glucosyltransferase domains of five tested large clostridial glucosyltransferases were successfully
introduced into cells as chimeric fusions to the CDTa adapter domain (CDTaN). Cell uptake was
demonstrated by the analysis of cell morphology, cytoskeleton staining, and intracellular substrate
glucosylation. The fusion toxins were functional only when the adapter domain of CDTa was
N-terminally located, according to its native orientation. Thus, like other binary toxins, the CDTaN/b
system can be used for standardized delivery systems not only for bacterial ADPRTs but also for a
variety of bacterial glucosyltransferase domains.
Keywords: binary toxins; Clostridium difficile; ADP-ribosyltransferase; glucosyltransferase;
protein delivery
Key Contribution: This is the first description of the binary toxin CDT as a cell biological tool for
intracellular delivery of enzymatically active allogenic toxin domains.
1. Introduction
Clostridioides difficile is a nosocomial pathogen that causes antibiotic-associated infections with
mild to severe diarrhea, pseudomembranous colitis, toxic megacolon, or death, depending on the
severity of the infection [1].
Pathogenic strains produce two main pathogenicity factors, i.e., toxin A (TcdA) and B (TcdB),
which glucosylate Rho GTPases within the host cell cytosol [2]. Besides these single-chain AB toxins,
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some C. difficile strains produce a binary AB toxin called CDT [3]. In a 2008 survey, approximately
23% of 389 C. difficile isolates from 34 European countries tested positive for CDT [4]. In the last few
decades, this binary toxin has come into focus as it occurs in the so-called hypervirulent C. difficile
strains associated with higher morbidity and mortality [5–7].
Together with Clostridium botulinum C2 toxin, Clostridium perfringens iota toxin, Clostridium spiroforme
toxin (CST), and Bacillus cereus/thuringiensis vegetative insecticidal proteins (VIP), CDT belongs to the
family of binary ADP-ribosylating toxins. These binary toxins consist of two separate components:
an enzymatically active ADP-ribosyltransferase (ADPRT) fused to an adapter and a binding and
translocation component. Because of high sequence identity and structural similarities between iota
toxin, CST, and CDT, these toxins are further classified as iota-like binary toxins [8,9].
CDTa contains an N-terminal signal sequence which is cleaved by proteolysis leaving an active
48 kDa protein [10]. Crystal structure analysis revealed that this protein has a two-domain structure,
with the C-terminal portion being the ADPRT, and the N-terminal portion necessary for binding
to CDTb [11]. Structure–function studies with iota toxin and Bacillus anthracis protective antigen,
which shares 36% sequence identity with CDTb, provided information about CDTb domain structure
that resulted to consist of an N-terminal activation domain I followed by domain II, necessary for
membrane insertion and pore formation, domain III, which is involved in oligomerization, and the
C-terminal domain IV, providing receptor binding [9]. The latter domain can be exchanged among
CDTb, Ib (iota toxin binding component), and CSTb (CST binding component) without affecting the
delivery of the enzymatic component (CDTa, Ia, or CSTa) [8], as they share the same receptor on host
cells, namely, the lipolysis stimulated lipoprotein receptor (LSR) [12,13]. In the proposed model of
uptake, the 99 kDa protein CDTb is activated by a serine protease, leaving an active 75 kDa fragment
which binds to LSR and oligomerizes into heptamers. Whether oligomerization occurs before or after
binding to the receptor is still unclear. However, after binding of CDTa, the CDTa/b complex is taken
up into cells via receptor-mediated endocytosis. A decrease of the endosomal pH induces membrane
insertion and pore formation by the CDTb oligomers, followed by translocation of CDTa into the
cytosol. Inside the cytosol, CDTa ADP-ribosylates monomeric actin, leading to depolymerization of
actin filaments and, therefore, breakdown of the actin cytoskeleton [14].
The delivery of the enzymatic component into the host cell cytosol by binary toxins is a highly
complex but efficient process. In recent years, researchers have exploited this system as a molecular
tool for the transport of different cargo into cells [15]. The B. anthracis binary toxin was one of the first
binary delivery systems used for the transport of heterologous proteins or DNA. For example, fusion
of the protein of interest to the lethal factor (LF) provides efficient uptake of this protein into target cells
when applied with protective antigen (PA), the binding component of B. anthracis binary toxin [16].
To date, the PA/LF system is the only one that has been used for delivery of a glucosyltransferase
domain [17]. Binary toxins belonging to the family of ADP-ribosylating binary toxins are as well useful
transport systems for the uptake of fusion proteins. The C2 toxin was extensively studied for the
delivery of, e.g., C3 toxin from Clostridium limosum [18] or Staphylococcus aureus [19] as a C2–C3 fusion
protein, Salmonella enterica virulence factor SpvB as a C2IN–C/SpvB fusion protein [20], biotinylated
proteins bound to a C2IN–streptavidin fusion protein [21], or p53 as a C2IN–p53 fusion protein [22]
into the cytosol. Besides C2 from C. botulinum, the iota toxin is also suitable as a transport system for
C3 [23].
To date, CDT has not yet been described as a transporter system. Here, we show that this
system is effective in introducing fusion proteins into cells and is therefore an alternative to other
binary toxin systems. We show that CDTb is eligible to transport large CDTaN fusion proteins, like
the glucosyltransferases from C. difficile TcdA and TcdB, Clostridium sordellii lethal toxin (LT) and
hemorrhagic toxin (HT), and Clostridium novyi α-toxin, into the cytosol, maintaining their functionality,
as we confirmed with appropriate assays.
Toxins 2018, 10, 225 3 of 15
2. Results
2.1. Cloning and Characterization of CDT
The complete open reading frame of cdta and cdtb were amplified by PCR from genomic DNA of
C. difficile clade 2 hypervirulent strain R20291. The 1392 bp (CDTa) and 2631 bp (CDTb) (Figure 1A)
fragments were ligated into pGEX-2T vector and were used for subsequent cloning of the mature
proteins lacking their first 42-amino acid (aa) leader sequence for export. Mature CDTa (aa 43–63) and
CDTb (aa 43–876) were expressed as GST fusion proteins. Whereas mature CDTa was released from
GST by thrombin, GST–CDTb was directly digested by trypsin to result in activated CDTb (Figure 1B).
In the following, CDTa and CDTb always stand for mature CDTa and activated CDTb, respectively,
if not indicated otherwise. The enzymatic activity of CDTa was tested in ADP-ribosylation assays.
The filmless autoradiography showed [32P]ADP-ribosylation of 42 kDa α-actin in HEp-2 cell lysates
(Figure 1C). Purified α-actin from rabbit muscle was also [32P]ADP-ribosylated. There was no evidence
of auto-[32P]ADP-ribosylation of 48 kDa CDTa (Figure 1C, right panel), as it is known from other classes
of bacterial ADP-ribosyltransferases [24]. ADP-ribosylation of α-actin from HEp-2 cell lysates and
purified α-actin was also tested in a gel shift assay where ADP-ribosylation of actin leads to a higher
apparent molecular mass (Figure 1D). After characterization of the ADP-ribosyltransferase activity of
CDTa, we tested functional CDTb in combination with CDTa in cell culture assays. The combination
of CDTa and CDTb induced typical cell rounding as a consequence of the destruction of the actin
cytoskeleton after 5 hours (Figure 1E). Neither CDTa nor CDTb alone induced any morphological
effects on HEp-2 cells.
2.2. C-Terminal Fusion Proteins are Delivered into Target Cells
After successful characterization of CDT, we started to genetically engineer fusion proteins
of the CDTa adaptor domain (CDTaN) which comprises the amino acids 1–226 of the mature
protein. First, we fused the glucosyltransferase domain of C. difficile TcdB (amino acids 1–543) to
CDTaN. Two different constructs were made with the glucosyltransferase domain (GTD) fused either
C-terminally to CDTaN (CDTaN-TcdB1–543) or N-terminally (TcdB1–543-CDTaN) (Figure 2A).
Both constructs were first tested for their glucosyltransferase activity in an in vitro glucosylation
assay. Figure 2B shows a representative immunoblot of HEp-2 cell lysates incubated with
CDTaN–TcdB1–543 as well as with TcdB1–543–CDTaN that was probed with the glucosylation-sensitive
anti-Rac1 antibody (Transduction Laboratories, clone 102) [25]. In cell lysates incubated with either
fusion protein, a TcdB1–543-catalyzed glucosylation of the substrate GTPase Rac1 was observed.
Non-glucosylated Rac1 was decreased to about 80% compared to untreated cell lysate. GAPDH
was used as a reference for protein loading. The C- and N-terminal fusion proteins were subsequently
tested in cell culture assays to investigate the intracellular delivery of these toxin domains by the
CDTaN/b delivery system. Since glucosylation of Rho-family GTPases induces complete cell rounding,
these morphological changes served as the end point for a first screening. The micrographs shown
in Figure 2C clearly evidenced that the CDTaN/b system successfully delivered the 60 kDa sized
glucosyltransferase domain of TcdB into the cytosol of HEp-2 cells. This was, however, the case
only if the GTD was fused C-terminally to CDTaN. The opposite construct TcdB1–543-CDTaN was not
introduced into the target cells, as shown by the unchanged control morphology. Cells treated with
only the CDTaN fusion proteins were also unaffected, thereby validating a CDTb-dependent delivery.
The intracellular action of TcdB1–543 was additionally and specifically tested by probing cell lysates
with glucosylation-sensitive anti-Rac1 (Figure 2D). Only in cells treated with CDTaN–TcdB1–543 in the
presence of CDTb, a decreased level of non-glucosylated Rac1 was observed.
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(ORF) of cdta (1392 bp) and cdtb (2631 bp) were amplified from genomic DNA of Clostridium difficile 
strain R20291; (B) The mature proteins CDTa (aa 43–463) and CDTb (aa 43–876) were expressed as 
GST fusion proteins. Whereas CDTa (48 kDa) was cleaved by thrombin from the GST tag, GST–CDTb 
was directly incubated with trypsin, resulting in the activated CDTb (75 kDa), as shown in Coomassie-
stained SDS-PAGE; (C) The in vitro ADP-ribosyltransferase activity of CDTa was tested in a [32P]ADP-
ribosylation assay. Filmless autoradiography shows in vitro [32P]ADP-ribosylated α-actin of HEp-2 
cell lysates (left panel) and α-actin from rabbit muscle (middle panel). The right panel shows no auto-
ADP-ribosylation of CDTa; (D) A gel shift assay of rabbit muscle α-actin (Coomassie staining) and α-
actin from lysates of CDT-treated HEp-2 cells (immunoblot from whole cell assay) shows different 
apparent migration of ADP-ribosylated actin in SDS-PAGE; (E) Cell culture assay proving that 
CDTa/b was functional. HEp-2 cells were incubated with the subunit CDTb (1 µg/mL), the subunit 
CDTa (3 µg/mL), or the combination of CDTa and CDTb at their respective concentrations. Only 
combined CDTa and CDTb induced morphological changes compared to the untreated control cells. 
Scale bars represent 10 µm. 
Figure 1. Cloning and functional characterization of recombinant CDT. (A) The open reading frames
(ORF) of cdta (1392 bp) and cdtb (2631 bp) were amplified from genomic DNA of Clostridium difficile
strain R20291; (B) The mature proteins CDTa (aa 43–463) and CDTb (aa 43–876) were expressed
as GST fusion proteins. Whereas CDTa (48 kDa) was cleaved by thrombin from the GST tag,
GST–CDTb was directly incubated with trypsin, resulting in the activated CDTb (75 kDa), as shown in
Coomassie-stained SDS-PAGE; (C) The in vitro ADP-ribosyltransferase activity of CDTa was tested in a
[32P]ADP-ribosylation assay. Filmless autoradiography shows in vitro [32P]ADP-ribosylated α-actin of
HEp-2 cell lysates (left panel) and α-actin from rabbit muscle (middle panel). The right panel shows no
auto-ADP-ribosylation of CDTa; (D) A gel shift assay of rabbit muscle α-actin (Coomassie staining) and
α-actin from lysates of CDT-treated HEp-2 cells (immunoblot from whole cell assay) shows different
apparent migration of ADP-ribosylated actin in SDS-PAGE; (E) Cell culture assay proving that CDTa/b
was functional. HEp-2 cells were incubated with the subunit CDTb (1 µg/mL), the subunit CDTa
(3 µg/mL), or the combination of CDTa and CDTb at their respective concentrations. Only combined
CDTa and CDTb induced morphological changes compared to the untreated control cells. Scale bars
represent 10 µm.
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shown in the bar graph (means ± SD, n = 7); (C) CDTaN–TcdB1–540 but not TcdB1–543–CDTaN (each 500 
ng/mL) induced typical cell rounding of HEp-2 cells only when delivered by CDTb (1 µg/mL). Scale 
bars represent 20 µm; (D) The bar chart shows the relative amount of non-glucosylated Rac1 in HEp-
2 cells treated with the indicated proteins. Representative immunoblots of non-glucosylated Rac1 and 
GAPDH show the corresponding bands for evaluation. In contrast to the C-terminal fusion protein 
(CDTaN–TcdB1–543), the N-terminally fused glucosyltransferase (TcdB1–540–CDTaN) was not delivered 
into the cells. Shown are mean values ± standard deviation; n = 3–6. 
  
Figure 2. Validation of CDTb/CDTaN as a delivery system for the glucosyltransferase domain of TcdB.
(A) CDTaN constructs used in this study; (B) In vitro glucosyltransferase activity of TcdB1–543–CDTaN
and CDTaN–TcdB1–543. Glucosylation was tested in crude HEp-2 cell lysates separated by 12.5%
SDS-PAGE and detected by Western blot analysis using specific glucosylation-sensitive Rac1-antibody.
Rac1 glucosylation relative to GAPDH as a loading control was quantified, and the data are shown in
the bar graph (means ± SD, n = 7); (C) CDTaN–TcdB1–540 but not TcdB1–543–CDTaN (each 500 ng/mL)
induced typical cell rounding of HEp-2 cells only when delivered by CDTb (1 µg/mL). Scale bars
represent 20 µm; (D) The bar chart shows the relative amount of non-glucosylated Rac1 in HEp-2
cells treated with the indicated proteins. Representative immunoblots of non-glucosylated Rac1 and
GAPDH show the corresponding bands for evaluation. In contrast to the C-terminal fusion protein
(CDTaN–TcdB1–543), the N-terminally fused glucosyltransferase (TcdB1–540–CDTaN) was not delivered
into the cells. Shown are mean values ± standard deviation; n = 3–6.
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2.3. Application of the CDT Delivery System with a Variety of Glucosyltransferase Domains
To simplify the purification of CDTaN–TcdB1–543, we cloned the gene into the pQE30 vector,
obtaining the 6-His–CDTaN–TcdB1–543 fusion protein (see Figure 2A). The N-terminal 6-His tag had no
effect on the function of CDTaN–TcdB1–543 (Figure 3A). This positive result encouraged us to clone
the CDTaN fusion proteins of a variety of GTDs from different large clostridial glucosyltransferases.
Figure 3A illustrates that not only the GTD of TcdB, but also other GTDs, namely, those of C. sordellii,
TcsH and TcsL, and of C. novyi, TcnA, were successfully delivered into cells. Phase-contrast micrographs
showed typical cell rounding when the cells were treated with CDT, with all tested fusion toxins
(Figure 3A). Immunofluorescence staining of the actin and tubulin cytoskeleton was performed for
a more detailed analysis. In all cases, the actin cytoskeleton was affected, and only remnants of
filamentous actin were detected (Figure 3B). In CDTb/CDTaN–TcnA-treated cells, retraction fibers
with prominent actin filaments were observed, most probably due to a delayed effect induced by this
fusion toxin compared to others.
In our set of fusion toxins, we found CDTaN–TcdA to be rather instable, with >90% of degraded
protein (Supplementary Figure S1). Although CDTaN–TcdA showed transient cell rounding, we did
not include this toxin in Figure 3A,B. Instead, morphological changes are shown in supplemental Figure
S1. Rac1 glucosylation for all tested glucosyltransferases delivered by the CDTaN/b system is shown
in Figure 3C. Rac1 is the common substrate for all tested large clostridial glucosyltransferases [26], and
the amount of non-glucosylated Rac1 was only reduced when the fusion toxins were delivered by
CDTb. The Rac1 bands detected by glucosylation-sensitive anti-Rac1 antibody (clone 102, Transduction
Laboratories) account for Rac1 and truncated Rac, respectively, in HEp-2 cells and were glucosylated as
well by the toxins. The upper band was also detected by an anti-Rac1 antibody (clone 23A8, Upstate).
2.4. Cell Surface Binding of CDTaN Fusion Proteins
To further characterize the application of fusion toxins, we investigated cell surface binding
and inhibition of uptake. Since we previously detected cell surface binding of the isolated GTD of
TcdB [27], we also tested the binding of CDTaN–TcdB1–543 to the outer cell surface in the absence of
CDTb. Immunoblot analysis showed binding of CDTaN–TcdB1–543 as well as of CDTa to the cells even
in the absence of CDTb (Figure 4A).
Binding of CDTaN was validated by detection of all used CDTaN fusion toxins (Figure 4B).
The meaning of extracellular binding of CDTa is discussed later. Nevertheless, for uptake into the
cytosol, CDTb is mandatory. The translocation of CDTaN fusion proteins was induced by a pH shift
in endosomes, as it could be inhibited by the v-ATPase inhibitor bafilomycin A1 (Figure 4C). Here,
we also tested the neutralizing effect of our polyclonal rabbit serum raised against CDTa. The serum
completely inhibited cell rounding induced by CDTaN–TcdB1–543 over the observed time period of 6
hours (Figure 4D).
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Figure 3. Exploiting the CDT system for standardized delivery of various clostridial GTDs.
(A) Phase-contrast microscopy of cell rounding assays showing intracellular delivery of CDTa
and of all tested CDTaN fusion GTDs (CDTaN–TcdB1–543, CDTaN–TcsH1–542, CDTaN–TcsL1–543,
CDTaN–TcnA1–548). Scale bars in untreated controls represent 20 µm; (B) Immunofluorescence staining
of filamentous actin (red), tubulin (green), and the nucleus (blue) of cells treated with the indicated
fusion toxins in the absence or presence of CDTb. The scale bars represent 10 µm; (C) Indirect proof of
Rac1 glucosylation by immunoblot against non-glucosylated Rac1 verifies the intracellular modification
of the co mon substrate GTPase by all fusion toxins.
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Neutralization of CDTaN–TcdB1–543 by anti-CDTa rabbit serum within the cell culture assay. Scale 
bars in controls C and D represent 20 µm. 
3. Discussion 
In this study, we evaluated the C. difficile binary toxin CDT as a valuable cell biological tool for 
intracellular delivery of proteins. We briefly characterized our recombinant CDTa and CDTb with 
respect to ADP-ribosyltransferase activity in vitro and in cell culture assays. After validating the 
recombinant CDT system, we adapted the CDTaN/b delivery system for intracellular delivery of 
glucosyltransferase domains from different bacterial pathogenicity factors. Neither the description of 
CDT nor the use of binary toxins as Trojan horses for delivery of proteins into cells is new. The novelty 
of this study is that CDT was successfully adapted for protein delivery for the first time, 
demonstrating to be equivalent to the B. anthracis PA system and the C. botulinum C2 system. We 
Figure 4. Detection and neutralization of CDTaN fusion toxins. (A) Binding of CDTa and
CDTaN–TcdB1–543 to the outer cell surface detected by immunoblot analysis using anti-CDTa rabbit
serum; (B) Binding of all CDTaN fusion toxins and of TcdB1–543. Shown is the detection by
TcdB1–540-specific scFv-Fc VIF090_A6 (left panel) and by anti-CDTa rabbit serum (right panel);
(C) Inhibition of pH-dependent delivery of CDTa and CDTaN–TcdB1–543 by the v-ATPase inhibitor
bafilomycin A1; (D) Neutralization of CDTaN–TcdB1–543 by anti-CDTa rabbit serum within the cell
culture as ay. Scale bars in controls C and D represent 20 µm.
3. Discussion
In this study, we evaluated the C. difficile binary toxin CDT as a valuable cell biological tool for
intracellular delivery of pr te s. We bri fly char cterized our recomb nant CDTa and CDTb with
respect to ADP-ribosyltransferase activity in vitro and in cell culture assays. After validating the
recombinant CDT system, we adapted the CDTaN/b delivery system for intracellular delivery of
glucosyltransferase domains from different bacterial pathogenicity factors. Neither the description of
CDT nor the use of binary toxins as Trojan horses for delivery of proteins into cells is new. The novelty
of this study is that CDT was successfully adapted for protein delivery for the first time, demonstrating
to be equivalent to the B. anthracis PA system and the C. botulinum C2 system. We have shown that not
only ADPRTs, but also completely different enzymatically active proteins or protein domains can be
delivered into cells by binary toxins. This was reported before only in a single study using the PA–LFn
system [17]. Although CDTb has only 28% and 38% sequence identity with PA or C2II, respectively [28],
we here present the Iota-like CDTaN/b system as equivalent to the other binary delivery systems.
Several reports showed the employment of binary toxins for protein delivery, as summarized by
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Barth and Stiles [28]. A closer look reveals that most of all bacterial ADPRTs, especially exoenzymes
C3bot from C. botulinum and C3lim from C. limosum but also SpvB from Salmonella enterica, were
successfully delivered into cells [18,20,29–31]. The C2I–C3 fusion proteins have been tested primarily
on macrophages. The exoenzyme C3 fusion proteins, however, have the disadvantage of entering some
cells by two ways: by C3-specific uptake or by specific C2II-mediated uptake. The exoenzymes C3bot or
C3lim can enter macrophages without further transporting devices but enter these cells more efficiently
by exploiting the C2I/C2II delivery system [32]. Other reports clearly showed the uptake of isolated
C3bot not only into macrophages but also into a variety of cells, such as murine hippocampal HT22
cells, stem cell-derived neurons from mice, SH-SY5Y cells, or even Chinese hamster ovary cells (CHO)
by using vimentin as a binding structure [33–36]. Thus, by applying C2I–C3 fusion proteins, it is hard
to differentiate between specific C3 uptake and C2II-mediated uptake into cells. Our system clearly
validated a CDTb-dependent uptake of non-ADPRT fusion toxins. In our studies, we experienced that
CDTa and the fusion proteins of CDTaN bound to the cell surface of the target cells independently of
CDTb. This was shown by specific immunoblots against CDTa or TcdB1–543. Binding to cells did not
result in the translocation and intracellular action of the fusion toxins, which was only observed in the
presence of CDTb. The binding of CDTa to the cell surface is interesting for two reasons: (1) confocal
microscopy can hardly differentiate between the extra- and intra-cellular leaflets of vesicle membranes,
making functional assays for translocation inevitable to prove membrane translocation; (2) If CDTa
is membrane-associated, this might important for the intracellular localization of cargoes. Further
investigations have to show the intracellular localization and distribution to subcellular compartments
of binary fusion toxins. An eventual intracellular membrane association of proteins clearly limits
the range of application for this kind of carrier. Yet, we do not know the nature of the cell surface
interaction of CDTa. According to the amino acid sequence, it can be hypothesized that CDTa binds
cholesterol with its N-terminal part. Fantini and coworkers described a mirror code of the cholesterol
recognition amino acid consensus (CRAC) sequence (Figure 5) [37].
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Figure 5. Does CDTa possess a functional cholesterol binding site? A cholesterol recognition
amino acid consensus (CRAC) motif (L/V–X(1–5)–Y/F/W–X(1–5)–K/R) and the reversed CARC motif
(K/R–X(1–5)–Y/F/W–X(1–5)–L/V) can be found in the N-terminal 55-amino acid sequence of CDTa.
Although the CRAC motif and the reversed CARC motif are separated by 31 amino acids in CDTa,
which is more than it can be found in reference membrane-associated proteins shown by Fantini and
coworkers, we cannot exclude cholesterol binding for CDTa. Unfortunately, the 3D structure of CDTa
does not contain the first CRAC motif, giving no information about the vicinity of the CRAC and
CARC motifs (PDB code 2WN4).
Our present data reveal that CDTaN is not able to deliver N-terminally fused cargo into cells,
as it was known for iota toxin [23]. This is most probably due to impaired transition through the
pore built by CDTb oligomers. The small N-terminal 6×His tag, however, does not hamper the
function of CDTa. The non-functionality of N-terminal fused proteins is a disadvantage of the CDT
system, excluding cargoes, where a free N-terminus is required. In a set of experiments, we extended
the application of CDTaN fusion proteins for a trial study of standardized delivery of homologous
protein domains. As shown in Figure 3, CDTaN fusion proteins containing the pathogenic domains of
widely known large clostridial glucosyltransferases were introduced into cells under standardized
conditions. The translocation of CDTa or CDTaN fusion proteins occurred under acidic conditions, and
could be inhibited by bafilomycin A1. The typical morphotypes of cells treated with CDTaN fusion
GTDs corresponded with that known to be induced by full-length glucosyltransferases. This was
demonstrated by the appearance of the “sordellii-like” clustering morphotype which was also induced
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by CDTaN–TcsL1–543 and the patchy cell rounding induced by TcnA. Our experiments thus validated
the CDT system as a protein delivery system for pathogenic toxin domains, enzymes, or effector
proteins that do not possess autotransporter characteristics. A variety of effector proteins from
pathogenic bacteria that have glucosyltransferase activity, such as Legionella pneumoniae SetA or Lgt1as
well as the effector protein CT166 of Chlamydia trachomatis [38–40], were characterized by transfection
experiments. Our system offers an alternative approach to investigate the direct effects of such effector
proteins in target cells.
A further putative application, especially of the CDT homologous iota toxin from C. perfringens,
is the use in anti-cancer therapy. It is known that the lipolysis-stimulated lipoprotein receptor (LSR)
is overexpressed in cancer cells [41]. Iota toxin as well as CDT use this receptor to enter eukaryotic
cells. This makes binary toxins using LSR as a receptor an attractive tool to preferentially target cancer
cells, as previously described for iota toxin [42,43]. On the other hand, a clear disadvantage of the
CDT or iota system is that these toxins cannot be applied to cells that lack LSR without transduction of
the respective receptor [13,42]. The binary toxin systems additionally bear the advantage of possible
retargeting to cell-specific receptors by exchange of the receptor binding domain of the B subunits of
toxins. Likewise, the LF/PA system from B. anthracis was used in combination with the pathogenic
domain of TpeL to target oncogenic Ras [44]. These applications illustrate even a pharmacological
potential of binary toxins.
In summary, our study encourages the further use of the CDTaN/b system for delivery of a variety
of proteins, including antibody fragments (intrabodies). More research has to be done to evaluate the
intracellular localization and the nature of cargoes that can be delivered. Although the GTDs appear
to have a significant size of 60 kDa, these protein domains do not possess disulfide bonds, making
membrane translocation with accompanied pore transition more probable compared to proteins with a
more rigid tertiary structure. Thus, our data contribute to the validation of binary toxins as valuable
tools in cell biology.
4. Materials and Methods
4.1. Cloning of CDTa, CDTb, and CDTaN Fusion Proteins
The complete ORFs of CDTa and CDTb were amplified by PCR from genomic DNA of C. difficile
strain R20291 (GenBank: FN545816.1). Since both genes code for a 42-amino acid (126 base pair)-long
leader sequence for secretion of proteins, we only cloned the sequences bp 127–389 for CDTa and bp
127–2628 for CDTb into the pGEX-2T vector to genetically engineer the GST fusion proteins of the
mature CDTa and CDTb. CDTaN was also ligated into the pQE30 vector for generation of N-terminally
6xHis-tagged CDTaN fusion proteins. Table 1 lists the primers that were used for cloning.
Table 1. Primers used for cloning of the CDTa and CDTb constructs.
Name Base Sequence (3’-5’)
pGEX-2T constructs
CDTa (aa 1–463) s TAGGATCCAAAAAATTTAGGAAACATAAAAGGATTAG
CDTa (aa 44–463) s TTAGGATCCGTTTGCAATACTACTTACAAGGC
CDTa (aa 1–463) a ATGAATTCTTAAGGTATCAATGTTGCATCAAC
CDTb (aa 1–876) s TAAGATCTAAAATACAAATGAGGAATAAAAAGGTATTAAG
CDTb (aa 43–876) s TAAGATCTGAAATTGTAAATGAAGATATACTCCC
CDTb (aa 1–876) a ATGAATTCCTAATCAACACTAAGAACTAATAACTCTC
pQE30 constructs
CDTaN Bam s AATGGATCCGTTTGCAATACTACTTACAAGG
CDTaN Kpn a AATGGTACCATCATCTTTAAAATCAAGACTATTTAC
GTD TcdB Kpn s AATGGTACCATGAGTTTAGTTAATAGAAAACAGTTAG
GTD TcdB Hind a AATAAGCTTTTAAAGAGAACCTTCAAAATAATTCCTTTTATATTC
GTD TcdA Kpn s AATGGTACCATGTCTTTAATATCTAAAGAAGAG
GTD TcdA Hind a AATAABCTTTTAAAGAGATCCACCAGTATAATCTC
GTD TcnA Kpn s AATGGTACCATGCTTATAACAAGAGAACAATTAATG
GTD TcnA Hind a AATAAGCTTTTAGAGAGTTCTTCCTATATAAGTTTTTATC
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Table 1. Cont.
Name Base Sequence (3’-5’)
GTD TcsH Kpn s AATGGTACCATGTCTTTAATATCTAAAGATGAATTAATAAAAC
GTD TcsH Hind a AATAAGCTTTTAAAGAGATTCCTGAGTATAATCTCTTAC
GTD TcsL Kpn s AATGGTACCATGAACTTAGTTAACAAAGCCC
GTD TcsL Hind a AATAAGCTTTTAAAGTGCACCTTCAAAATAACC
4.2. Purification and Activation of CDTa and CDTb
GST–CDTa, GST–CDTaN–TcdB1–543 and GST–CDTb were expressed in Escherichia coli following a
standard protocol. Gene expression was induced by 100 µM isopropyl-β-D-thiogalactopyranosid
when the bacterial cultures reached an OD600 of 0.6. The GST fusion proteins were affinity
purified via glutathione-sepharose (GE Healthcare, Dornstadt, Germany) by gravity flow, and the
proteins of interest were released either by thrombin (0.06U/µg protein, 4 ◦C overnight for
CDTa and CDTaN–TcdB1–543) or by elution with 10 mM glutathione (CDTb). Eluted GST–CDTb
was directly activated by trypsin (0.2 µg/µg protein, 30 min at room temperature). Trypsin
was inactivated by 2 mM 4-(2-Aminoethyl)benzensulfonylfluorid, and the solution was dialyzed
against PBS overnight. The 6×His-tagged proteins were purified using Protino Ni-IDA columns
(Macherey-Nagel, Düren, Germany) following a standard protocol supplied by the manufacturer.
The elution buffer was exchanged via ZEBA desalting columns (Thermofisher, Bonn, Germany),
and the proteins were stored in 10 mM Tris-HCl, ph 7.4, 20 mM NaCl at −80 ◦C. In the following,
CDTa always means the mature protein without the leader sequence, and CDTb always stands for
trypsin-activated CDTb if not stated otherwise, since it was only used for cell culture experiments to
deliver CDTa and CDTaN fusion proteins into target cells.
4.3. In Vitro ADP-Ribosylation and Glucosylation Assays
ADP-ribosylation was performed with rabbit muscle actin (1 µg) or HEp-2 crude cell lysates
(100 µg) in 0.1 mL ribosylation buffer (20 mM HEPES, pH 7.4, 100 mM NaCl2, and 100 µM
NAD). For [32P]ADP-ribosylation, the buffer was additionally supplemented with 0.5 µCi [32P]NAD.
The reaction was started by addition of 200 ng CDTa per sample or as indicated and incubation for
45 min at 37 ◦C. The reaction was stopped by addition of 5-fold Laemmli buffer and heating at 95 ◦C
for 3 min. The samples were resolved by SDS-PAGE. Radioactive [32P]ADP-ribosylation was detected
by filmless autoradiography (Canberra Packard) of Coomassie-stained gels or by gel shift assay and
specific immunoblots in case of non-radioactive ADP-ribosylation. In vitro glucosylation of Rac1 was
performed by harvesting HEp-2 cells in glucosylation buffer (100 mM KCl, 1 mM UDP-glucose, 1 mM
MgCl2). The cells were homogenized by sonification, and 100 µL, containing 100 µg of proteins, was
used for glucosylation. To start the reaction, CDTaN–TcdB1–543 or TcdB1–543–CDTaN (300 ng each)
were added to the cell homogenates, and the reaction was incubated at 37 ◦C for 1 h. The reaction
was stopped by addition of Laemmli buffer and heating at 95 ◦C for 5 min, and Western blot with
glucosylation sensitive Rac1- antibody was performed.
4.4. Cell Culture and Cell Rounding Assay
HEp-2 cells were kept in Minimum Essential Medium (MEM) Eagle supplemented with 10% fetal
bovine serum, 100 µM penicillin, and 100 µg/mL streptomycin in a humidified atmosphere of 5% CO2
at 37 ◦C and passaged three times a week. For the experiments, cells were seeded in a defined volume
to reach a confluency of about 70% on the day of the experiment. For the cytotoxicity assays, the
cells were incubated with either 500 ng/mL of the CDTa or CDTaN constructs, 1000 ng/mL of CDTb,
or the combination of both at 37 ◦C for 4 h, if not stated otherwise. For the bafilomycin experiments,
the cells were pre-incubated with a concentration of 500 nM bafilomycin A1 (Calbiochem/Merck,
Darmstadt, Germany). In the case of the neutralization assays, 0.5 µL or 2.5 µL of CDTa-specific
polyclonal rabbit serum was pre-incubated with 500 ng/mL of CDTaN–TcdB1–543 at 37 ◦C for 15 min
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and added to the cells together with 1000 ng/mL of CDTb, followed by an incubation period at 37 ◦C
for 2 h. The morphological changes were documented by an Axiovert 200 microscope (Carl Zeiss,
Feldbach, Austria). To investigate the status of glucosylated Rac1, the cells were seeded in 3.5 cm
cell culture dishes and harvested in 100 µL Laemmli buffer after treatment with the CDTa/CDTaN
constructs and/or CDTb. After sonification for 3 s, the samples were incubated at 95 ◦C for 5 min and
subjected to SDS-PAGE and Western Blot.
4.5. Toxin Binding Assay
The extracellular binding of the CDTa and CDTaN fusion proteins to HEp-2 cells was investigated
by Western blot. The cells in 24-well plates were incubated with 2 µg/mL of CDTa and CDTa fusion
proteins in culture medium for 30 min at 4 ◦C. Afterwards, the cells were rinsed twice with PBS and
scraped off from the cell culture wells in 100 µL of Laemmli buffer. The samples were briefly sonicated
for lysis, heated at 95 ◦C, and subjected to SDS-PAGE and immunoblot.
4.6. Immunostaining and Fluorescence Microscopy
For immunostaining, HEp-2 cells were cultured in µ-Slide eight-well cell culture chambers
(ibidi GmbH, Planegg, Germany). Five hours after toxin treatment, the samples were fixed with
4% PFA in PBS at 4 ◦C for 10 min and directly used for staining. The fixed cells were blocked
and permeabilized in PBS supplemented with 5% milk powder and 0.3% Triton X-100 for 10 min
at RT. After blocking, the cells were incubated at 4 ◦C overnight in the primary antibody solution:
1 µg/mL mouse anti-tubulin antibody B-5-1-2 (Sigma-Aldrich, Hamburg, Germany) in 1% milk
powder-supplemented PBS (MPBS). The day after, the cells were incubated in goat anti-mouse IgG
Alexa 488 (A11001 Invitrogen/Thermo Fisher Scientific, Darmstadt, Germany) secondary antibody
solution for 1 h at RT in the dark. F-actin staining was performed with MPBS supplemented with
Phalloidin-iFluor 555 (AAT Bioquest, Sunnyvale, CA, USA), while counterstaining was carried out by
incubating the samples with 100 ng/mL DAPI (Thermo Fisher Scientific, Darmstadt, Germany) in PBS
for 10 min. At the end of every described step, the samples were washed three times with PBS for at
least 5 min.
The stained cells were imaged by a confocal laser scanning microscope (SP8, Leica Microsystems).
All the images were taken using constant acquisition parameters and were equally processed with
Leica Application Suite X (Leica Microsystems) and Fiji [45].
4.7. Generation of a Monoclonal Anti-TcdB Antibody
Antibodies against TcdB were selected in the scFv-format from the human naive antibody
gene libraries HAL9/10 [46]. The selection and screening were performed as described before [47].
In brief, for antibody selection, the scFv phages were incubated on TcdB1–1852, immobilized on Costar
High-Binding microtiter plates (Sigma-Aldrich Chemie GmbH, Munich, Germany). After three rounds
of panning, 94 clones were screened for the production of TcdB1–1852-binding scFvs by antigen ELISA.
After the identification of the scFv producing clones, plasmid DNA was isolated, and the antibody DNA
was sequenced. The scFv was recloned into pCSE2.6-hIgG1-Fc-XP using NcoI/NotI for mammalian
production as scFv-Fc, an IgG-like antibody format (VIF090_A6). The production and purification
were performed as described before [48].
4.8. Polyclonal Anti-CDTa Rabbit Serum
To obtain CDTa-specific polyclonal rabbit serum, a female New Zealand rabbit was immunized
with 100 µg purified recombinant CDTa in PBS. A boost was made 4 and 6 weeks after immunization,
again with 100 µg antigen each. Eight weeks after the first immunization, blood was collected, and
the anti-CDTa serum was tested for specificity. All animal treatments were performed according to
the national Protection of Animals Act (Permission No. 33-42502-03A351) at our central Laboratory
Animal Science.
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4.9. Western Blot
Proteins resolved by SDS-PAGE were transferred onto nitrocellulose by semi-dry blotting.
The nitrocellulose was blocked with 5% [w/v] non-fat dry milk powder in TBS-Tween (20 mM Tris,
pH 7.4, 50 mM NaCl, 0.02% [v/v] Tween-20) for 30 min. Specific first antibodies (1 µg/mL) were
applied in TBS-T over night at 4 ◦C. After washing with TBS-T, appropriate horseradish-conjugated
secondary antibodies were applied for 45 min. The nitrocellulose was washed three times with TBS-T,
and the detection of the bound antibodies was done by a chemiluminescence reaction (Supersignal
West femto, Pierce, Germany).
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/10/6/225/s1,
Figure S1: Instable CDTaN-TcdA1–542 fusion protein.
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